Author: ["Virginie Lacronique","Alexandre Mignon","Monique Fabre","Benoit Viollet","Nicolas Rouquet","Thierry Molina","Arlette Porteu","Alexandra Henrion","Dldier Bouscary","Paule Varlet","Virginie Joulin","Axel Kahn"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Fas is an apoptosis–signaling cell surface antigen that has been shown to trigger cell death upon specific ligand or antibody binding. Treatment of mice with an anti–Fas antibody causes fulminant hepatic failure due to massive apoptosis. To test a putative protective effect of the anti–apoptotic Bcl–2 protein, transgenic mice were generated to express the human bcl–2 gene product in hepatocytes. Early onset of massive hepatic apoptosis leading to death was observed in all nontransgenic mice treated with an anti–Fas antibody. By contrast, hepatic apoptosis was delayed and dramatically reduced in transgenic animals, yielding a 93% survival rate. These results demonstrate that Bcl–2 is able to protect from in vivoFas–mediated cytotoxicity, and could be of significance for preventing fulminant hepatic failure due to viral hepatitis in humans.Cite this article
Lacronique, V., Mignon, A., Fabre, M. et al. Bcl–2 protects from lethal hepatic apoptosis induced by an ant–Fas antibody in mice. Nat Med 2, 80–86 (1996). https://doi.org/10.1038/nm0196-80 